Analyst recommendations: Dell, Palo Alto Networks, Snowflake, Warner Bros, Stellantis...

Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information can be used to shed light on movements in certain stocks or on market sentiment towards a company.

• Cytokinetics, Incorporated: Goldman Sachs downgrades to neutral from buy with a price target reduced from USD 85 to USD 60.
• Dell Technologies Inc.: Barclays upgrades to equalweight from underweight with a target price of USD 97.
• First Industrial Realty Trust, Inc.: Wolfe Research upgrades to outperform from peerperform with a target price of USD 64.
• Littelfuse, Inc.: Stifel upgrades to buy from hold with a price target raised from USD 270 to USD 280.
• Palo Alto Networks, Inc.: Mizuho Securities upgrades to outperform from buy with a price target raised from USD 350 to USD 380.
• Sarepta Therapeutics, Inc.: Citi drops coverage on the stock.
• Snowflake Inc.: Mizuho Securities downgrades to outperform from buy with a price target reduced from USD 180 to USD 165.
• Warner Bros. Discovery, Inc.: Bernstein downgrades to market perform from outperform with a price target reduced from USD 10 to USD 8.
• Zoominfo Technologies Inc.: Daiwa Securities downgrades to neutral from outperform with a price target reduced from USD 15 to USD 9.
• Natera, Inc.: Piper Sandler & Co maintains its overweight recommendation and raises the target price from USD 120 to USD 150.
• Stellantis N.v.: RBC Capital maintains its outperform rating and reduces the target price from 24 to EUR 18.
• Bridgepoint Group Plc: JP Morgan upgrades to overweight from neutral with a target price raised from GBP 2.59 to GBP 3.58.